Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Yonghong Xu
Institution:
Affiliated Hospital of Qingdao University
Observed institution:
Affiliated Hospital of Qingdao University
ORCID:
0000-0002-8428-0577
Observed ORCID:
0000-0002-8428-0577
OpenAlex ID:
A5090226225
The systemic immune-inflammation index is superior to predicting clinical remission and relapse for ulcerative colitis patients treated with vedolizumab
2025
·
Jing Yan
, Jun Wu
, et al.
·
Frontiers in Medicine
·
7
The ulcerative colitis endoscopic index of severity score is superior to reflecting long-term prognosis in ulcerative colitis patients treated with vedolizumab
2023
·
Jing Yan
, Ailing Liu
, et al.
·
Medicine
·
6
Ustekinumab is effective against ulcerative colitis with intestinal stenosis: A case report
2022
·
Ailing Liu
, Jing Guo
, et al.
·
Medicine
·
5
Real-life effectiveness and safety of vedolizumab in moderate-to-severe ulcerative colitis: A single-center experience in Northern China
2024
·
Jing Yan
, Xueli Ding
, et al.
·
Medicine
·
4
Clinical value of the systemic immune-inflammation index in patients with Crohn disease
2026
·
Jing Yan
, Rongkun Wang
, et al.
·
Medicine
·
1
Association of nutritional indices with early clinical remission in patients with moderate-to-severe ulcerative colitis treated with vedolizumab
2026
·
Hao Zhang
, Yueyuan Wang
, et al.
·
Therapeutic Advances in Gastroenterology
Show more works
View as search
Works count:
6
Citation count:
23
H-index:
4
I10-index:
Year
Topic
Type